Compare iShares MSCI ACWI ETF (ACWI) vs Baxter International Inc (BAX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
iShares MSCI ACWI ETF vs Baxter International Inc — how do they compare? iShares MSCI ACWI ETF trades at $155.73, while Baxter International Inc trades at $22.05 (market cap $11.81B). The key difference: Baxter International Inc pays a 0.87% dividend while iShares MSCI ACWI ETF pays none, and iShares MSCI ACWI ETF is trading nearer its 52-week high, Baxter International Inc nearer its low. Which is the better fit depends on your goals.
| ACWI | BAX | |
|---|---|---|
52-Week High | $159.97 | $30.66 |
52-Week Low | $128.32 | $15.80 |
Market Cap | — | $11.81B |
Sector | — | Health |
Enterprise Value | — | $19.48B |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACWI trades at $157.97, up 1.17% with a bullish technical signal from moving averages. The ETF shows strong institutional interest and positive news flow, with a dividend scheduled for June 2026. Key support lies at $156, while resistance is at $159.
Outlook remains positive due to robust EPS growth and investor inflows into global equity ETFs. Risks include overbought technical conditions and market volatility. The stock's valuation and momentum support a constructive view for long-term investors.
Baxter International (BAX) trades at $22.86, up 0.93% today, near the consensus price target of $22.67. The stock shows a bullish technical trend with recent earnings beats in Q1 2026, though profitability remains weak with a negative net income margin of -9.7% and ROE of -16.73%. Cash flow trends indicate operational challenges, with net cash flow negative in recent periods. Recent news highlights sustainability initiatives and strategic partnerships, supporting a turnaround narrative amid ongoing financial restructuring.
Outlook: BAX presents a mixed opportunity with analyst consensus leaning Hold (52.77%) amid valuation concerns (P/E 87.85) and persistent losses. Key risks include high debt, margin pressure, and execution hurdles in stabilizing the business. Upside potential exists if operational improvements and AI integration drive sustained earnings recovery, but investors should weigh the high volatility and competitive pressures in the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI ACWI ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.
Read more on ACWI →About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →
